These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22586600)

  • 1. Nanoparticle theories slowly turn into practice.
    Bender E
    Cancer Discov; 2011 Sep; 1(4):280. PubMed ID: 22586600
    [No Abstract]   [Full Text] [Related]  

  • 2. Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous.
    Markman M
    Cancer; 2010 Nov; 116(22):5116-8. PubMed ID: 20665504
    [No Abstract]   [Full Text] [Related]  

  • 3. Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance?
    Edelman MJ
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):127-9. PubMed ID: 12722869
    [No Abstract]   [Full Text] [Related]  

  • 4. [Recent proposals for early stage clinical trials of cancer].
    Ohashi Y
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():292-4. PubMed ID: 7986106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology evaluation: PK1, Pfizer/Cancer Research UK.
    Bilim V
    Curr Opin Mol Ther; 2003 Jun; 5(3):326-30. PubMed ID: 12870445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials referral resource. Current clinical trials for the proteasome inhibitor PS-341.
    Wright J; Hillsamer VL; Gore-Langton RE; Cheson BD
    Oncology (Williston Park); 2000 Nov; 14(11):1589-90, 1593-4, 1597. PubMed ID: 11125942
    [No Abstract]   [Full Text] [Related]  

  • 7. [Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance].
    Chen JN; Shen Q; Li SS
    Yao Xue Xue Bao; 2009 Apr; 44(4):333-7. PubMed ID: 19545047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Q&A: Geoffrey Shapiro on phase I drug trials. Spoke with Suzanne Rose.
    Shapiro G
    Cancer Discov; 2013 Oct; 3(10):1089. PubMed ID: 24124216
    [No Abstract]   [Full Text] [Related]  

  • 9. Progress in the delivery of nanoparticle constructs: towards clinical translation.
    Ryan SM; Brayden DJ
    Curr Opin Pharmacol; 2014 Oct; 18():120-8. PubMed ID: 25450066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials referral resource. Current clinical trials of fenretinide.
    Swerdlow RD; Zwiebel JA; Gravell AE; Cheson BD
    Oncology (Williston Park); 2001 Dec; 15(12):1595-6, 1598, 1600. PubMed ID: 11780702
    [No Abstract]   [Full Text] [Related]  

  • 11. Nanoparticle technologies for cancer therapy.
    Alexis F; Pridgen EM; Langer R; Farokhzad OC
    Handb Exp Pharmacol; 2010; (197):55-86. PubMed ID: 20217526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrin inhibitors reaching the clinic.
    Stupp R; Ruegg C
    J Clin Oncol; 2007 May; 25(13):1637-8. PubMed ID: 17470853
    [No Abstract]   [Full Text] [Related]  

  • 13. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].
    Andoh M; Fujiwara Y; Shimada Y
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
    Carden CP; Sarker D; Postel-Vinay S; Yap TA; Attard G; Banerji U; Garrett MD; Thomas GV; Workman P; Kaye SB; de Bono JS
    Drug Discov Today; 2010 Feb; 15(3-4):88-97. PubMed ID: 19961955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of nanoparticles in cancer: drug delivery and diagnostics.
    Talekar M; Kendall J; Denny W; Garg S
    Anticancer Drugs; 2011 Nov; 22(10):949-62. PubMed ID: 21970851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials referral resource. Current clinical trials of epothilone B analog (BMS-247550).
    Colevas AD; West PJ; Cheson BD
    Oncology (Williston Park); 2001 Sep; 15(9):1168-9, 1172-5. PubMed ID: 11589064
    [No Abstract]   [Full Text] [Related]  

  • 17. Towards the use of nanoparticles in cancer therapy and imaging.
    Pauwels EK; Erba P
    Drug News Perspect; 2007 May; 20(4):213-20. PubMed ID: 17637933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current status and issues in clinical trials of anticancer agents].
    Kojima H
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of caution.
    Markman M
    Cancer; 2007 Oct; 110(8):1644-7. PubMed ID: 17879372
    [No Abstract]   [Full Text] [Related]  

  • 20. EPO-906 (Novartis).
    Galmarini CM; Dumontet C
    IDrugs; 2003 Dec; 6(12):1182-7. PubMed ID: 14666430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.